Dermatology · Bronx, NY
NPI
1972645307
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
3620 E Tremont Ave
Bronx, NY, 10465
Phone (718) 792-4700
Groups this clinician bills Medicare through
Medicare paid, 2024
$204K
7,001 services
Medicare patients, 2024
506
Average age 73
Drug cost, 2024
$746K
3,020 prescriptions
Company payments, 2025
$1,063
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Louisa M Tift was code 17003 (destruction skin lesion), 2,312 times for 254 patients. In total Louisa M Tift billed 7,001 services in 47 codes, and Medicare paid $204K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-06-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 2,312 | 254 | $6.03 | $14K |
| 95044 Test - Miscellaneous | Office | 2,041 | 26 | $4.50 | $9,174 |
| 99213 Office E&M - Established | Office | 626 | 357 | $74.11 | $46K |
| 17000 Destruction Skin Lesion | Office | 476 | 262 | $45.16 | $21K |
| 11102 Skin Biopsy | Office | 322 | 234 | $79.07 | $25K |
| 17110 Destruction Skin Lesion | Office | 189 | 139 | $98.71 | $19K |
| 11103 Skin Biopsy | Office | 157 | 94 | $46.63 | $7,321 |
| 99212 Office E&M - Established | Office | 144 | 88 | $45.91 | $6,611 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 118 | 53 | $0.73 | $85.87 |
| 99214 Office E&M - Established | Office | 104 | 75 | $103.69 | $11K |
| 99203 Office E&M - New | Office | 75 | 75 | $86.96 | $6,522 |
| 11900 Skin | Office | 73 | 44 | $39.80 | $2,905 |
| 11901 Skin | Office | 44 | 13 | $55.68 | $2,450 |
| 17262 Destruction Skin Lesion | Office | 26 | 17 | $147.92 | $3,846 |
| 10060 Skin | Office | 22 | 20 | $102.67 | $2,259 |
By year: 2022 $179K for 5,793 services; 2023 $212K for 6,760 services; 2024 $204K for 7,001 services.
Medicare prescription drug claims, 2024
In 2024, the drug Louisa M Tift prescribed most often to Medicare patients was Ketoconazole, with 422 prescriptions and refills. In total Louisa M Tift wrote 3,020 Medicare prescriptions that cost $746K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 422 | 467 | 193 | $6,316 |
| Mometasone Furoate Generic | 356 | 383 | 225 | $7,944 |
| Ammonium Lactate Generic | 246 | 266 | 141 | $3,373 |
| Mupirocin Generic | 177 | 179 | 142 | $1,340 |
| Tacrolimus Generic | 158 | 171 | 77 | $27K |
| Triamcinolone Acetonide Generic | 144 | 150 | 97 | $2,013 |
| Clobetasol Propionate Generic | 144 | 147 | 76 | $8,818 |
| Metronidazole Generic | 127 | 147 | 66 | $4,900 |
| Levocetirizine Dihydrochloride Generic | 125 | 182 | 57 | $970 |
| Hydrocortisone Generic | 83 | 83 | 58 | $606 |
| Ciclopirox Ciclopirox Olamine | 73 | 79 | 40 | $2,081 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 67 | 67 | 49 | $4,080 |
| Ciclopirox Generic | 59 | 61 | 30 | $3,168 |
| Clindamycin Phosphate Generic | 57 | 58 | 23 | $1,543 |
| Doxycycline Hyclate Generic | 46 | 46 | 33 | $418 |
Brand drugs: 339 claims; generic drugs: 2,681 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Louisa M Tift $1,063 ($1,063 in general payments such as food, travel and fees) from 14 companies. The largest payer was Janssen Biotech, Inc. with $246.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 8 | $246 |
| Incyte Corporation INCY | 6 | $152 |
| Abbvie Inc. ABBV | 6 | $139 |
| Lilly USA, LLC LLY | 4 | $111 |
| Genzyme Corporation SNY | 5 | $86.93 |
| LEO Pharma Inc. | 4 | $76.79 |
| Pfizer Inc. PFE | 3 | $62.04 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $38.33 |
| Kerecis Limited | 1 | $32.77 |
| Cipher Pharmaceuticals US LLC CPH.TO | 1 | $28.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.